Kay Kay 66
commented on
$SRIVARU Holding (SVMH.US)$
SVMH (SRIVARU Holding) shows high speculative potential, with a current oversold level indicating a possible short-term rebound. At $0.028, the stock is heavily discounted, with strong support at $0.026. If it holds, there’s significant upside, aiming for a recovery towards the resistance at $0.174—a potential gain of over 500%.
SVMH (SRIVARU Holding) shows high speculative potential, with a current oversold level indicating a possible short-term rebound. At $0.028, the stock is heavily discounted, with strong support at $0.026. If it holds, there’s significant upside, aiming for a recovery towards the resistance at $0.174—a potential gain of over 500%.
3
4
$Lyra Therapeutics (LYRA.US)$
The recent developments reported in Lyra Therapeutics’ latest 8-K filing present a mixed picture for investors:
Positive Aspects:
1. Cost Reduction: The workforce reduction is aimed at cutting operating expenses, which could improve the company’s financial health and increase shareholder value in the long run. This move shows the company’s proactive approach to managing costs and resources efficiently.
2. Retention of Key Executives: The approv...
The recent developments reported in Lyra Therapeutics’ latest 8-K filing present a mixed picture for investors:
Positive Aspects:
1. Cost Reduction: The workforce reduction is aimed at cutting operating expenses, which could improve the company’s financial health and increase shareholder value in the long run. This move shows the company’s proactive approach to managing costs and resources efficiently.
2. Retention of Key Executives: The approv...
5
1
Kay Kay 66
reacted to and commented on
$Sunshine Biopharma (SBFM.US)$
Hey Moomoo community,
I wanted to share some insights and updates regarding Sunshine Biopharma (SBFM) to help us navigate the current challenges many of us are facing.
Recent Financial Performance:
• Positive Q1 2024 Results: SBFM reported better-than-expected earnings per share (EPS) of -$2.00, significantly improving from the expected -$8.00. The company also posted revenues of $7.54 million, exceeding the forecasted...
Hey Moomoo community,
I wanted to share some insights and updates regarding Sunshine Biopharma (SBFM) to help us navigate the current challenges many of us are facing.
Recent Financial Performance:
• Positive Q1 2024 Results: SBFM reported better-than-expected earnings per share (EPS) of -$2.00, significantly improving from the expected -$8.00. The company also posted revenues of $7.54 million, exceeding the forecasted...
9
3
Kay Kay 66
reacted to
$Citius Pharmaceuticals (CTXR.US)$
Hey Moomoo community,
I wanted to provide an updated analysis on $Citius Pharmaceuticals (CTXR.US)$ to help us all stay informed and navigate our investment decisions.
Recent Developments:
1. Financial Performance:
• Q1 2024 Results: Citius reported a better-than-expected performance in Q1 2024, with significant developments including the resubmission of the Biologics License Application (BLA) fo...
Hey Moomoo community,
I wanted to provide an updated analysis on $Citius Pharmaceuticals (CTXR.US)$ to help us all stay informed and navigate our investment decisions.
Recent Developments:
1. Financial Performance:
• Q1 2024 Results: Citius reported a better-than-expected performance in Q1 2024, with significant developments including the resubmission of the Biologics License Application (BLA) fo...
8
Kay Kay 66
liked
$Citius Pharmaceuticals (CTXR.US)$
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Citius Pharmaceuticals, a late-stage biopharmaceutical company, announced a scheduled investor call to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. The call will take place on Monday, June 3, 2024, at 8:30 AM ET. Citius Chairman and CEO, Leonard Mazur, alongside the management team, will add...
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Citius Pharmaceuticals, a late-stage biopharmaceutical company, announced a scheduled investor call to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. The call will take place on Monday, June 3, 2024, at 8:30 AM ET. Citius Chairman and CEO, Leonard Mazur, alongside the management team, will add...
1
Kay Kay 66
liked
$Selina Hospitality (SLNA.US)$ runnnnnn
2
2
Kay Kay 66 OP TheDylz : If SVMH is indeed conducting an offering at $0.07, this means they are issuing new shares at a price higher than the current market price ($0.028). Offerings can dilute the value of existing shares, as more shares are added to the market, potentially lowering the stock price further. However, since the offering is above the current price, it can also set a floor or indicate that the company or investors believe in higher intrinsic value.